Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cushing's Syndrome and Fibrolamellar Carcinoma Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRKACA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRKACA Wild-Type Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View PRKACA Products |
| Disease Mutant | PRKACA L206R Mutant Protein Cushing's syndrome driver mutant. High Purity, Sequence Verified. |
View PRKACA L206R Products |
| Fusion Target | DNAJB1-PRKACA Fusion Protein Recombinant chimeric driver kinase for Fibrolamellar Hepatocellular Carcinoma. |
View DNAJB1-PRKACA Products |
| Gene Delivery | PRKACA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target engagement assays. |
View PRKACA Products |
| Benchmark Ab | Anti-PRKACA Recombinant Antibody Recombinant positive control for Western Blot and ELISA validation. |
View PRKACA Products |
| Validator | PRKACA siRNA Set For target knockdown and specificity verification. |
View PRKACA Products |
| Related Target A | PRKACB Close homolog (PKA C-beta) required for off-target selectivity screening. |
View PRKACB Products |
| Related Target B | DNAJB1 Chimeric fusion partner in fibrolamellar hepatocellular carcinoma (FL-HCC). |
View DNAJB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against close homolog PRKACB | High-purity PRKACB recombinant proteins available for parallel counter-screening. |
| Targeting Cushing's-specific L206R mutant | L206R mutant proteins strictly verified by mass spectrometry and sequence analysis. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PRKACA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRKACA therapeutics is intensifying, with major players shifting focus from traditional non-selective kinase inhibitors to mutation-specific small molecules and fusion-directed therapies. As first-generation pan-PKA inhibitors reach clinical evaluation, the next wave of R&D is targeting the driver mutation L206R in adrenocortical adenomas and the DNAJB1-PRKACA fusion kinase in fibrolamellar hepatocellular carcinoma (FL-HCC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective Inhibitors) | Blueprint Medicines, Academic Spin-offs | Cushing's Syndrome, Adrenocortical Adenoma | Selectivity Assay (Need Mutant vs WT and PRKACB Proteins) |
| PROTAC / Degraders | Biotech Startups, University Labs | Fibrolamellar Hepatocellular Carcinoma (FL-HCC) | Target Engagement Validation (Need Lentivirus for Stable Cell Lines) |
| siRNA / Gene Therapy | Preclinical R&D Programs | Adrenal Hyperplasia, Rare Oncology | Knockdown Validation (Need High-Purity siRNA & qPCR Controls) |